I am so grateful for this forum and want to thank you for what you are doing here. It is so hard to find accurate and expert information out there with this very scary disease.
I am 38, was diagnosed with Stage IIIC OVCA and had optimal debulking surgery on 4/29/10. I am on my 7th round of carbo/taxol (was originally scheduled for 6 but had a partial bowel obstruction causing a temporary rise in CA125). They also thought that Chemo #6 could possibly not have been properly absorbed and that the IP port caused problems, possibly infection. All that resolved, my CA125 just before this 7th chemo is at 13. This is to have been my last treatment.
I am wanting to request one more chemo just to get it into single digits and was told by another doctor from Northwestern (in an over the phone consult) that he was reluctant to stop 1st line chemo as long as the CA125 continued to go down and then would often do one or two more after that. This particular doctor at Northwestern believes that Hexalen is a good choice of drug once you are finished with traditional chemo regimen.
I would love to know your opinion on continuing chemo as long as there is a continued reduction in CA125 numbers, as well as your thoughts on Hexalen.
thank you for your question. We have all wondered about what is the right number of treatments. There is no wrong answer here.
It has fallen out of favor, but it used to be standard to perform a second look surgery after 6 cycles of chemo to decide about further chemo. That surgery involved a big laparotomy and lots of biopsies . If cancer was identified, another 6 cycles of chemo were given.
if no cancer was found, we would stop. This was in the 1980's and 1990's
Then people started trying to do the same thing with laparoscopy instead of subjecting women to a huge incision.But laparoscopy is terribly inaccurate.You just cannot get underneath adhesions, behind the liver, and so forth.
And no one could prove that 12 was better than 6 cycles .
And by the new century, off a clinical trial, the practice stopped.
So now the standard is 6 or 8 and then we wait until there are signs of recurrence
it is not very satisfying is it?
there have been two recent studied looking at giving maintenance therapy after carbo taxol
one with a year of taxol which showed a longer time to recurrence but terrible neuropathy and lower quality of life
and the recent one with avastin (bevicizumab) which shows a 3.7 month increase progression free interval but no survival data.
hard to know what to do with that.
SO for you, there are two ways to look at this CA 125 of 13
it could be that that is where you live and it will never be lower and that has nothing to do with ovarian cancer presence
or it could be that the level reflects a clone of cells that is persistent and chemotherapy resistant.
if the CA 125 is because of of # 1 - getting more chemo does not make sense and increases permanent neuropathy
If reason # 2 is true, then you should not get more carbo taxol because what is there is resistant to that chemo and it is time to think of a clinical trial and a different agent.
how to sort that out? PET scan? or laparoscopy or another laparotomy or just wait and see with serial CA 125 blood tests?
these are the issues to discuss with your oncologist
Thank you so much for getting back with me so quickly. It seems that it is just so hard to get access to information when it comes to OVCA, and I really appreciate you sharing yours through this forum.
My onc has not recommended a second look surgery, although I wish they would so this. It seems as if it might improve some of our odds. I have gotten CT scans, but to my knowledge not PET scans (though I was told they use a combination here at Sloan), so a little confused about that, and assume PET scans are more accurate?
I also wondered if you had any thoughts you might share on Hexalen?
Again, thank you so, so much for what you are doing here!
hexalen is an effective chemo drug that has been used in recurrent ovarian cancer.
I do not think there is much experience with it for maintenance chemo
it is an oral agent
I got this from a nice site:http://www.drugs.com/pro/hexalen.html#splSectionAdverseReactions
With continuous high-dose daily Hexalen® capsules, nausea and vomiting of gradual onset occur frequently. Although in most instances these symptoms are controllable with anti-emetics, at times the severity requires Hexalen® capsules dose reduction or, rarely, discontinuation of Hexalen® capsules therapy. In some instances, a tolerance of these symptoms develops after several weeks of therapy. The incidence and severity of nausea and vomiting are reduced with moderate-dose administration of Hexalen® capsules. In 2 clinical studies of single-agent Hexalen® capsules utilizing a moderate, intermittent dose and schedule, only 1 patient (1%) discontinued Hexalen® capsules due to severe nausea and vomiting.
Peripheral neuropathy and central nervous system symptoms (mood disorders, disorders of consciousness, ataxia, dizziness, vertigo) have been reported. They are more likely to occur in patients receiving continuous high-dose daily Hexalen® (altretamine) capsules than moderate-dose Hexalen® capsules administered on an intermittent schedule. Neurologic toxicity has been reported to be reversible when therapy is discontinued. Data from a randomized trial of Hexalen® capsules and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity; however, it adversely affected response duration suggesting that pyridoxine should not be administered with Hexalen® capsules and/or cisplatin (1).
Hexalen® capsules causes mild to moderate dose-related myelosuppression. Leukopenia below 3000 WBC/mm3 occurred in <15% of patients on a variety of intermittent or continuous dose regimens. Less than 1% had leukopenia below 1000 WBC/mm3. Thrombocytopenia below 50,000 platelets/mm3 was seen in <10% of patients. When given in doses of 8-12 mg/kg/day over a 21 day course, nadirs of leukocyte and platelet counts were reached by 3-4 weeks, and normal counts were regained by 6 weeks. With continuous administration at doses of 6-8 mg/kg/day, nadirs are reached in 6-8 weeks (median).
Data in the following table are based on the experience of 76 patients with ovarian cancer previously treated with a cisplatin-based combination regimen who received single-agent Hexalen® capsules. In one study, Hexalen® capsules, 260 mg/m2/day, was administered for 14 days of a 28 day cycle. In another study, Hexalen® capsules, 6-8 mg/kg/day, was administered for 21 days of a 28 day cycle.
ADVERSE EXPERIENCES IN 76 PREVIOUSLY TREATED OVARIAN CANCER PATIENTS RECEIVING SINGLE-AGENT Hexalen® CAPSULES Adverse Experiences % Patients
Nausea and Vomiting
Mild to Moderate
Increased Alkaline Phosphatase
Peripheral Sensory Neuropathy
Moderate to Severe
Anorexia and Fatigue
Platelets 60 mg%
Copyright 1994-2017MedHelp International.All rights reserved. MedHelp is a division of Aptus Health.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.